Followers | 74 |
Posts | 3281 |
Boards Moderated | 0 |
Alias Born | 03/16/2014 |
Wednesday, May 18, 2022 8:53:25 AM
NovoCure initiated at buy at Wainwright on base business expansion, phase 3 readouts
By No Author Named
(Seeking Alpha)
H.C. Wainwright has initiated NovoCure (NASDAQ:NVCR) with a buy rating citing international expansion of its core business and four phase 3 studies with readouts expected from 2022-2024.
The firm has a $115 price target (~76% upside based on Friday's close).
Analyst Emily Bodnar said that even though its base business generates ~$500M in sales annually, NovoCure (NVCR) treatments can still benefit from international approvals as the company "focuses on life cycle management with additional studies and next-generation arrays on the horizon for 2022.
She highlighted upcoming results from several late-stage studies: the LUNAR study for stage 4 non-small cell lung cancer (NSCLC) later this year; the METIS study for brain metastases from NSCLC in 2023; and the PANOVA-3 study for pancreatic cancer in 2024.
"We believe there is a significant buying opportunity, and there is value to unlock at current levels assuming only one ongoing Phase 3 study readouts positive," Bodnar wrote.
NovoCure's (NVCR) pipeline is based on the company's Tumor Treating Fields technology, which works by blocking cell division (mitosis) in cancer.
Read why Seeking Alpha contributor Shareholders Unite said NovoCure (NVCR) is a buy for the patient investor.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM